A resist composition comprising a quencher in the form of an amine compound having a highly polar lactone or sultone ring and an acid labile group in a common molecule is provided. The resist composition has a high sensitivity and forms a pattern with improved LWR or CDU, independent of whether it is of positive or negative tone.

A secondary battery includes a positive electrode, a negative electrode, and an electrolytic solution where (A) the electrolytic solution contains a solvent and an electrolyte salt, the solvent containing ethylene carbonate, (B) a content of the electrolyte salt is from 0.8 mol/kg to 2.0 mol/kg both inclusive, (C) a content of the ethylene carbonate in the solvent is from 10 wt % to 30 wt % both inclusive, (D) a ratio M2/M1 of a number M2 of moles of the ethylene carbonate to a number M1 of moles of the electrolyte salt is from 0.4 to 2.4 both inclusive, and (E) the electrolytic solution contains at least one of sulfone compounds.

A secondary battery includes a positive electrode, a negative electrode, and an electrolytic solution where (A) the electrolytic solution contains a solvent and an electrolyte salt, the solvent containing ethylene carbonate, (B) a content of the electrolyte salt is from 0.8 mol/kg to 2.0 mol/kg both inclusive, (C) a content of the ethylene carbonate in the solvent is from 10 wt % to 30 wt % both inclusive, (D) a ratio M2/M1 of a number M2 of moles of the ethylene carbonate to a number M1 of moles of the electrolyte salt is from 0.4 to 2.4 both inclusive, and (E) the electrolytic solution contains at least one of sulfone compounds.

In one aspect, the disclosure relates to prodrug compositions of a STAT inhibitor compound. In some aspects, the STAT is STAT3. Disclosed are pharmaceutical compositions comprising the prodrug inhibitors of STAT. In various aspects, the prodrug inhibitors of STAT can be used in methods of treating an inflammatory disorder, including multiple sclerosis, or a disorder of uncontrolled cellular proliferation, such as a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

In one aspect, the disclosure relates to prodrug compositions of a STAT inhibitor compound. In some aspects, the STAT is STAT3. Disclosed are pharmaceutical compositions comprising the prodrug inhibitors of STAT. In various aspects, the prodrug inhibitors of STAT can be used in methods of treating an inflammatory disorder, including multiple sclerosis, or a disorder of uncontrolled cellular proliferation, such as a cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

In one embodiment, the present application discloses compounds that are selective neuroactive agents for the treatment of diseases of the central nervous system (CNS). In one aspect, the neuroactive agents are NCDs of metal chelates, including complexes of iron, copper or zinc.

In one embodiment, the present application discloses compounds that are selective neuroactive agents for the treatment of diseases of the central nervous system (CNS). In one aspect, the neuroactive agents are NCDs of metal chelates, including complexes of iron, copper or zinc.

An ammonium salt having a saccharin anion, which is represented by formula (1), exhibits excellent thermal stability even though no halogen atom is contained therein.

##STR00001##

(In the formula, each of R.sup.1-R.sup.4 independently represents an alkyl group having 1-4 carbon atoms or an alkoxyalkyl group that is represented by —(CH.sub.2).sub.n—OR (wherein R represents an alkyl group having 1-4 carbon atoms, and n represents an integer of 1 or 2). Incidentally, any two of the R.sup.1-R.sup.4 may combine with each other to form a ring together with a nitrogen atom.)